Objectives To profile the outcome of multiple myeloma (MM) patients treated at a South
African tertiary hospital in KwaZulu-Natal (KZN) and to compare MM in HIV-negative patients …

Simple Summary Cereblon (CRBN) is a direct binding target of immunomodulatory drugs
(IMiDs) that are commonly used to treat multiple myeloma (MM). Many patients with MM …

Background: In the West, the median age at diagnosis of multiple myeloma is 66 years, with
only 2% of patients diagnosed below the age of 40 years. The median age at diagnosis of …

Plasma cell dyscrasias are a mixed bag of plasma cell malignancies and include indolent
monoclonal gammopathy of undetermined significance (MGUS) at one end of the spectrum …

Myeloma patients with high involved free light chains (iFLC) at diagnosis may exhibit a
worse clinical course, independent of established prognostic factors. This study aimed to …

Introduction: Limited data exist on interphase fluorescent in situ hybridization (iFISH)-based
survival outcomes in newly diagnosed multiple myeloma (NDMM) from India. Objectives: To …

The recent study by Veerendra et al.[1] described outcomes of 106 patients with myeloma
over a seven-year period and focused on differences in disease characteristics and survival …

Renal outcomes in myeloma associated acute kidney injury; a single centre experience Page 1
Journal of Renal Injury Prevention J Renal Inj Prev. 2022; 11(x): 32020. Renal outcomes in …

Abstract Management of Metastatic Humeral Disease is based on a systematic review of
published studies surrounding the management of metastatic disease, multiple myeloma …

Background: Hematological disorders require a systematic approach, from clinical
examination to a complete blood count, followed by a bone marrow study for diagnosis. To …